VTGN compared with IFRX: revenue, margins and what each company keeps, and the suppliers and customers both name

VTGNVistagen Therapeutics, Inc.

Mkt capRevenueRevenue

IFRXInflaRx N.V.

Mkt capRevenueRevenue

Compare

VTGNVistagen Therapeutics, Inc.

IFRXInflaRx N.V.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only VTGN 4

—Pherin Pharmaceuticals, Inc. (Pherin)unlistedsupplier

—AffaMedunlistedcustomer

—AffaMed Therapeuticsunlistedcustomer

—Fuji Pharmaunlistedcustomer

Shared 0

No disclosed counterparties: IFRX.

Only IFRX 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

VTGNVistagen Therapeutics, Inc.

0.17▲+2.06%· post 0.17

Mkt cap$7.3MRevenue$1MQ1 FY27Revenue$1MFY26

IFRXInflaRx N.V.

1.31▼−3.32%· post 1.31

ClosedNov 6 '26

Mkt cap$94.3MRevenue—Revenue—

Compare

ClosedNov 6 '26

VTGNVistagen Therapeutics, Inc.

IFRXInflaRx N.V.

0.17▲+2.06%post 0.17

Price

1.31▼−3.32%post 1.31

$7.3M

Mkt cap

$94.3M

Q1 FY27$1M

Revenue

—

FY26$1M

Revenue

—

VTGN0.17▲+2.06%vsIFRX1.31▼−3.32%ClosedNov 6 '26